DB17343ExperimentalCell transplant therapies
ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.
- Also known as
- 123b-33bcCAR · CD123-CD33cCAR T-cells · ICG136:CD123-CD33cCAR T-cells
- Code names
- ICG-136
Which companies are running trials of ICG-136, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account